ProjektDAPT-Shock AMI – Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial InfarctionDAPT-SHOCK-AMI study
Grunddaten
Akronym:
DAPT-Shock AMI
Titel:
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial InfarctionDAPT-SHOCK-AMI study
Laufzeit:
01.06.2022 bis 31.12.2024
Abstract / Kurz- beschreibung:
Objective: Comparison of the effect of parenteral Cangrelor with the recommended treatment with Ticagrelor to:
1) adenosine diphosphate (ADP) activated platelet aggregation, and
2) occurrence of major cardiovascular events
in patients with acute myocardial infarction, initially in cardiogenic shock.
Study population: Cardiogenic shock complicating acute myocardial infarction
Intervention: Cangrelor IV initially on the top of standard antiplatelet therapy
Primary endpoint – laboratory: Comparison of the effect of parenteral Cangrelor with the recommended Ticagrelor treatment on adenosine diphosphate activated platelet aggregation.
Primary endpoint – clinical: Comparison of the effect of parenteral Cangrelor with the recommended Ticagrelor treatment on the incidence of major cardiovascular events (Death, Myocardial Infarction, or Stroke) in patients with acute myocardial infarction initially in cardiogenic shock 30 days after enrolment in the study.
1) adenosine diphosphate (ADP) activated platelet aggregation, and
2) occurrence of major cardiovascular events
in patients with acute myocardial infarction, initially in cardiogenic shock.
Study population: Cardiogenic shock complicating acute myocardial infarction
Intervention: Cangrelor IV initially on the top of standard antiplatelet therapy
Primary endpoint – laboratory: Comparison of the effect of parenteral Cangrelor with the recommended Ticagrelor treatment on adenosine diphosphate activated platelet aggregation.
Primary endpoint – clinical: Comparison of the effect of parenteral Cangrelor with the recommended Ticagrelor treatment on the incidence of major cardiovascular events (Death, Myocardial Infarction, or Stroke) in patients with acute myocardial infarction initially in cardiogenic shock 30 days after enrolment in the study.
Beteiligte Mitarbeiter/innen
Leiter/innen
Medizinische Universitätsklinik und Poliklinik (Department)
Kliniken und klinische Institute, Medizinische Fakultät
Kliniken und klinische Institute, Medizinische Fakultät
Medizinische Fakultät
Universität Tübingen
Universität Tübingen
Weitere Mitarbeiter/innen
Medizinische Fakultät
Universität Tübingen
Universität Tübingen
Lokale Einrichtungen
Abteilung Innere Medizin III
Medizinische Universitätsklinik und Poliklinik (Department)
Kliniken und klinische Institute, Medizinische Fakultät
Kliniken und klinische Institute, Medizinische Fakultät
Geldgeber
Prag, Tschechien
Kooperationen
Prag, Tschechien